Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study for SerpinPC in Hemophilia B Treatment

16">The study aims to determine the effectiveness of SerpinPC in reducing bleeds in individuals with hemophilia B. Hemophilia B is a rare genetic disorder that affects the blood's ability to clot properly, leading to prolonged bleeding and increased risk of complications. Current treatment options for hemophilia B include regular infusions of clotting factors, but these can be costly and time-co..